S1P (sphingosine 1-phosphate) is a signalling molecule involved in a host of cellular and physiological functions, most notably cell survival and migration. S1P, which signals via a set of five Gprotein-coupled receptors (S1P1-S1P5), is formed by the action of two SphKs (sphingosine kinases) from Sph (sphingosine). Interfering RNA strategies and SphK1 (sphingosine kinase type 1)-null (Sphk1 − / − ) mouse studies implicate SphK1 in multiple signalling cascades, yet there is a paucity of potent and selective SphK1 inhibitors necessary to evaluate the effects of rapid onset inhibition of this enzyme. We have identified a set of submicromolar amidine-based SphK1 inhibitors and report using a pair of these compounds to probe the cellular and physiological functions of SphK1. In so doing, we demonstrate that our inhibitors effectively lower S1P levels in cell-based assays, but we have been unable to correlate SphK1 inhibition with changes in cell survival. However, SphK1 inhibition did diminish EGF (epidermal growth factor)-driven increases in S1P levels and Akt (also known as protein kinase B)/ERK (extracellular-signal-regulated kinase) phosphorylation. Finally, administration of the SphK1 inhibitor to wild-type, but not Sphk1 − / − , mice resulted in a rapid decrease in blood S1P levels indicating that circulating S1P is rapidly turned over.
INTRODUCTION
S1P (sphingosine 1-phosphate) is a bioactive lipid implicated in a host of biological functions, including cell migration [1] [2] [3] and survival [4, 5] as well as angiogenesis [6] . S1P exerts its effects via five G-protein-coupled receptors, S1P1-S1P5 [7] , and perhaps through less well-defined intracellular targets. Owing in part to the remarkable clinical success of the S1P receptor agonist and immunomodulatory pro-drug, fingolimod (FTY720) [8] , S1P signalling pathways are currently the subject of many investigations.
SphK1 (sphingosine kinase type 1) and SphK2 (sphingosine kinase type 2) are solely responsible for S1P synthesis by catalysing the phosphorylation of Sph (sphingosine) [9, 10] .
Studies with Sphk1
− / − mice reveal that SphK1 is responsible for a substantial fraction of circulating S1P [11] . These kinases have come under increasing scrutiny as drug targets owing to their role in the production of S1P and the SphK-S1P axis has been linked to cell growth, survival, angiogenesis and metastasis [12, 13] .
SphK1 and SphK2 play a role in controlling the relative concentrations of S1P and its precursor, Sph, and this proposed homoeostatic mechanism has been referred to as the 'sphingolipid rheostat' [14] . The implication of this concept is that SphK inhibition would simultaneously decrease S1P levels and increase concentrations of Sph and its precursor, ceramide. The concept of a sphingolipid homoeostasis, reinforced by numerous studies using interfering RNA strategies, suggests SphKs are important drug targets for the treatment of conditions characterized by hyperproliferation such as fibrosis and cancer. The relative importance of SphK1 compared with SphK2 as a drug target remains a topic of debate with some studies indicating SphK1 [15] [16] [17] [18] , whereas other studies point towards SphK2 [19, 20] as the most significant. The present study is focused on SphK1.
Previously described SphK inhibitors are of relatively low potency (K i values >1 μM) [21] and for most of these compounds their influence on the Sph/S1P ratio in either cells in culture or in whole animals has not been reported [22] [23] [24] [25] . Furthermore, many of the existing inhibitors are long-chain bases that, like Sph, are toxic to cells at micromolar concentrations [26] . We recently discovered an amidine-based scaffold of SphK inhibitors that has allowed us to generate potent (K i <0.2 μM) and selective SphK1 inhibitors [27, 28] . In the present paper, we describe the use of an enantiomeric pair of these inhibitors. We observed that acute SphK1 inhibition results in a pronounced, rapid decrease in S1P levels in both cultured cells and mice. In agreement with the mitogenic effects of S1P, we found that EGF (epidermal growth factor)-induced phosphorylation of Akt (also called protein kinase B) and ERK (extracellular-signal-regulated kinase) in SKOV3 cells was antagonized by our inhibitor. We failed to observe, however, a direct effect of our inhibitor on the survival of U937 and Jurkat T-cells.
MATERIALS AND METHODS

Materials
Compounds 1a and 1b were synthesized as described in [28] .
Sphk1
− / − mice were a gift from Dr R. Proia (National Institute of Diabetes and Digestive and Kidney Disease), Bethesda, MD, U.S.A.). Compound SKI-II was purchased from Sigma-Aldrich. C57BL/6j mice were from Jackson Laboratories. Antibodies against ERK, p (phospho-) ERK, Akt, pAkt, PARP [poly(ADPribose) polymerase] and caspase 3 were purchased from Cell Signaling Technology. Plasmids encoding DAG (diacylglycerol) kinase α and DAG kinase ζ were gifts from Dr Kaoru Goto (Yamagata University School of Medicine, Yamagata, Japan) and Dr Matthew Topham (University of Utah, Salt Lake City, UT, U.S.A.) respectively. C 17 -S1P and C 17 -Sph were purchased from Avanti Polar Lipids.
Kinase assays
SphK activity was measured by a scintillation proximity assay as we described previously [21] . Briefly, recombinant SphK1 or SphK2 were incubated in 96-well FlashPlates (PerkinElmer) with D-erythro-Sph and [γ -
33 P]ATP, and the [ 33 P]S1P product, which adheres to the plate wall, was quantified by scintillation counting. To assay ceramide kinase and DAG kinases, the recombinant proteins were incubated with [γ - 32 P]ATP and substrate (C 6 -ceramide and 1-O-hexadecyl-2-acetyl-sn-glycerol respectively) and the lipid product, after recovery by organic extraction, was resolved by TLC, detected by autoradiography and quantified by liquid scintillation counting. These assays were performed with or without a fixed concentration of inhibitor and the effect on K m and V max was determined.
Lipid extraction
Extraction protocols and LC (liquid chromatography)-MS procedures were from Shaner et al. [29] with minor modifications. Cell pellets (approximately 5 million cells) or whole blood (20 μl) were mixed with 2 ml of a 3:1 methanol/chloroform mixture and transferred to a capped glass vial. To this suspension was added 10 μl of internal standard solution containing 1 μM C17 S1P, 1 μM C17 Sph and 1 μM of an undecyl analogue of 1a and 1b (dodecyl). The mixture was homogenized in a bath sonicator for 10 min and incubated at 48
• C for 16 h. The mixture was then cooled to ambient temperature (22
• C) and mixed with 200 μl of 1 M KOH in methanol. The samples were again sonicated and incubated at 37
• C for 2 h. After this time, the samples were neutralized through the addition of 20 μl of acetic acid and transferred to 2 ml microcentrifuge tubes. Samples were then centrifuged at 10 000 g for 10 min at 4
• C. The supernatant fluid was collected in a separate glass vial and the pellets discarded. The resulting solution was evaporated under a stream of nitrogen gas. Immediately before LC-MS analysis, the material was dissolved in 300 μl of methanol and centrifuged at 12 000 g for 12 min at 4
• C. Then 50 μl of the resulting supernatant fluid was analysed by LC-MS.
LC-MS protocol
Analyses were performed by LC-electrospray ionization-MS using a triple quadrupole mass spectrometer (Sciex 4000 QTrap) coupled to a Shimadzu LC-20AD LC system. A binary solvent gradient with a flow rate of 1 ml/min was used to separate sphingolipids and drugs by reverse-phase chromatography using a Supelco Discovery C 18 column (50 mm × 2.1 mm, 5 μm bead size). Mobile phase A consisted of water/methanol/formic acid (79:20:1, by vol.), whereas mobile phase B was methanol/formic acid (99:1, v/v). The run started with 100 % solvent A for 0.5 min. Solvent B was then increased linearly to 100 % solvent B over 5.1 min and held at 100 % for 4.3 min. The column was finally re-equilibrated to 100 % solvent A for 1 min. Natural sphingolipids were detected using MRM (multiple reaction monitoring) methods described previously [29] as follows: C 17 -S1P (366.4→250.4); S1P (380.4→264.4); dhS1P (dihydroS1P) (382.4→266.4); C 17 -Sph (286.4→250.3); Sph (300.5→264.4); and dhSph (sphinganine) (302.5→260.0). Fragmentation of compounds 1a and 1b was analysed by direct infusion of 1 μM solutions in methanol/formic acid (99:1, v/v) and the following transitions were found to produce the most intense product ions in positive mode: C 12 -proline-amidines 1a and 1b (386.3→273.1); and VPC96077 (C 11 -proline-amidine) (372.5→259.2). All analytes were analysed simultaneously using the aforementioned MRM methods. Voltages [DP (declustering potential), EP (entrance potential), CE (collision energy) and CXP (cell exit potential)] for 1a and 1b were 35, 10, 25 and 6, and 156, 10, 25 and 14 V respectively. Retention times for all analytes under our experimental conditions were between 5.1 and 5.6 min. The following ceramides were measured by monitoring the m/z 264.4 product ion as described previously [29] using a Supelco Supelcosil LC-NH 2 column (50 mm × 2.1 mm, 3 μm bead size): 12:0, 16:0, 18:1 and 24:1. Quantification was carried out by measuring peak areas using commercial software (Analyst 1.5.1).
Cell culture
U937 and Jurkat T-cells were grown as described in [22] . Briefly, cells were grown in RPMI 1640 medium supplemented with L-glutamate, 10 % FBS (fetal bovine serum) and penicillin/streptomycin at 37
• C in an atmosphere containing 5 % CO 2 . SKOV3 cells were grown in McCoy's 5a medium supplemented with 10 % FBS and penicillin/streptomycin at 37
• C in an atmosphere containing 5 % CO 2 . At 24 h before adding inhibitors, the growth medium was replaced with medium containing 0.5 % or 2 % FBS.
Western blot analysis
Cells were incubated with various concentrations of inhibitor for the times indicated (usually 2 h). After incubation, cells were washed with PBS and lysed using a Dounce homogenizer. Equal amounts of protein were resolved by SDS/PAGE using 10 % polyacrylamide gels and resolved proteins were transferred on to a nitrocellulose membrane. Membranes were blocked with 5 % (w/v) non-fat dried skimmed milk powder in TBS (Trisbuffered saline, pH 7.4) containing 0.1 % Tween 20 for 1 h at room temperature. After rinsing, membranes were incubated with antibodies (diluted 1:1000 in TBS) against ERK, pERK, Akt, pAkt, caspase 3, PARP or β-actin for 1 h. After washing three times in TBS, the nitrocellulose membrane was incubated with a 1:2000 dilution (in TBS) of HRP (horseradish peroxidase)-conjugated anti-IgG antibody. Detection was accomplished by chemiluminesence using a commercial kit (PerkinElmer Western Lightning).
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] cell viability assay
U937 and separately Jurkat T-cells were plated in a 96-well plate at a density of 5-6 × 10 4 cells per well. Cells were grown overnight in 2 % FBS and then treated with the indicated concentration of compound overnight. The TACS TM MTT assay was performed according to the manufacturer's protocol (R&D Systems). Briefly, MTT reagent (10 μl per 100 μl of cell-culture medium) was added to each well and the plate was incubated at 37
• C for 4 h, followed by incubation with detergent reagent at room temperature for 2 h. Absorbance was measured at a wavelength of 570 nm.
Pharmacokinetic analysis
Groups of 8-12-week-old mice (strain: C57BL/6j) were anaesthetized with methoxyflurane and injected into the tail vein with 1a, 1b (dose: 10 mg/kg) and/or an equal volume of vehicle. The vehicle was a 2 % solution of HPCD (hydroxypropyl-β-cyclodextrin) (Cargill Cavitron 82004) in water. After injection, animals were lightly anaesthetized and bled from the retro-orbital sinus at the specified time points (initial time points were 1-2 min after dosing). Blood was extracted immediately as described above for lipid and drug analysis. Animal protocols were approved before experimentation by the University of Virginia's School of Medicine Animal Care and Use Committee.
RESULTS
Inhibitor design strategy
We have described previously a set of SphK inhibitors with an amidine 'warhead' [27] . A homology model suggests that the amidine group interacts directly with ATP via a bidentate chelation of the γ -phosphate [28] . In the design of biologically active small molecules, rigid analogues are a structural motif often used to improve selectivity among related targets. For example, we found that restricting the rotatable bonds of FTY720 analogues has a significant impact on their rate of phosphorylation by SphK1 and SphK2 [30] . To increase selectivity and potency for SphK1, we designed a rigid analogue of our previously reported amidinebased SphK inhibitors. The limited rotational degrees of freedom of rigid analogues were expected to provide greater structural differences between stereoisomers. Indeed, the enantiomers of our proline analogue exaggerated the differences in activity at SphK1 over those described in our initial study [27] . Our structureactivity relationship studies also identified the 12 carbon alkyl tail-length analogues as the most potent for SphK inhibition [27, 28] . Taking these structural considerations into account, we selected enantiomers 1a and 1b (structures in Table 1 ) for in-depth characterization.
Evaluation of 1a and 1b in vitro
We first determined the K i values of 1a and 1b at SphK isotypes by measuring the synthesis of [ 33 P]S1P catalysed by recombinant SphK1 and SphK2 [21] . In agreement with our previous findings [27] , the S-enantiomer (1a), derived from Lproline, was significantly more potent at SphK1 than its Rcounterpart (1b). Owing to their enantiomeric nature, comparing these compounds in biological systems is useful in establishing the target selectivity of the inhibitors. Importantly, there is a >100-fold difference in potency between 1a (K i 0.1 μM) and 1b (K i 16 μM) at SphK1, thus differences in biological responses to these compounds can reasonably be assigned to activity at SphK1. Our amidine-based SphK1 inhibitors, including 1a and 1b, are competitive with Sph, but not with ATP. Therefore as a further assessment of selectivity, we tested 1a at related lipid kinases including ceramide kinase and DAG kinase isotypes α and ζ . At a concentration of 3 μM, there was no inhibition of these lipid kinases (results not shown). 
Evaluation of 1a and 1b on cultured cells
We next determined whether the inhibitors were capable of penetrating cells and inhibiting SphK1 therein. Owing to high levels of SphK1 expression and ease of culture, we chose human monocyte U937 cells as our primary model system for the evaluation of SphK1 inhibitors [31] . Spiegel and co-workers had also evaluated their mono-methylated Sph analogue SKI-1 using U937 cells thus affording comparison of SphK1 inhibitors while recognizing possible differences in strains of U937 cells [22] . We treated U937 cultures with either enantiomer and quantified the accumulation of cell-associated S1P, dhS1P, Sph, dhSph and 1a or 1b. As depicted in Figure 1 , treatment of cultures with 1a or 1b for 2 h resulted in diminished S1P (Figure 1a ) and dhS1P ( Figure 1b ) in a drug concentration-dependent manner. As predicted from assessment at recombinant SphK1, enantiomer 1a was significantly more potent than 1b; the IC 50 value for 1a was approximately 0.03 μM, whereas the IC 90 value was approximately 0.3 μM. Concomitant with the decrease in the phosphorylated species, both Sph and dhSph levels rose on treatment with 1a, but the extent of the increase was 2-fold or less (Figure 1c) . The decrease in S1P was observed as soon as 10 min after inhibitor addition (results not shown) and persisted for at least 24 h (Figure 1a) . The amount of cell-associated 1a and 1b increased proportionately to added compound and significant amounts of compound remain cell-associated after 24 h (Figure 1d ). One abundant ceramide species, C 16:0 -ceramide, was also slightly increased after 2 h and significantly elevated after 24 h of 1a, but not 1b, treatment (Figure 1e) . A similar increase, albeit to a lesser extent, was also observed with C 18:1 -and C 24:1 -ceramides (results not shown). These data are consistent with the observations reported by Paugh et al. [22] . Treatment of another cell line, human T-cell leukaemia Jurkat T-cells, for 2 h with 1a (but not 1b) also resulted in decreased S1P and increased Sph levels (Figures 1f and 1g) , although the magnitude of the changes were less than with U937 cells. To confirm that the observed decrease in S1P accumulation in response to 1a was the result of decreased synthesis (as opposed to increased degradation/export), we added exogenous Sph and measured S1P in U937 cells with/without 1a in the culture medium. Cells supplemented with Sph to 0.3 or 1 μM exhibited pronounced increases in both Sph and S1P after 2 h (Figure 2) . The concomitant addition of 1a to 0.3 μM largely blocked the appearance of S1P (Figure 2a) while exaggerating the accumulation of Sph (Figure 2b ). These results indicate that the decrease in S1P levels observed in U937 cells treated with 1a is primarily the result of blockade of SphK1 activity. Presumably, the decreased S1P levels observed as a consequence of 1a treatment (Figure 1a ) occur because S1P metabolism by phosphatases and/or S1P lyase and/or S1P export proceeds unimpeded, whereas synthesis is blocked. These results also document that the inhibitors are readily taken up by U937 and Jurkat T-cells.
The ability to block SphK activity in U937 cells enabled an examination of cell signalling and survival by these cells in response to the blockade. A previous study documenting the effects of another SphK1 inhibitor, SKI-1 (SphK1 K i 10 μM), on U937 cells ascribed decreased cell survival to the blockade of S1P biosynthesis [22] . Specifically, treatment with 20 μM of SKI-1 blocked the constitutive phosphorylation of ERK and Akt that is characteristic of U937 cells [22] . Therefore we asked whether treatment with 1a (K i 0.1 μM) might have similar effects on ERK and Akt phosphorylation by U937 cells. As depicted in Figure 3 , we did not detect a change in ERK phosphorylation with 1a at 0.3 μM, a concentration that results in a substantial blockade of S1P synthesis (see Figures 1 and 2) . Effects on ERK phosphorylation were observed only at high 1a concentration (10 μM) or after prolonged exposure times (>2 h). We observed a similar pattern for Akt phosphorylation, although even longer exposure times (16 h) were required to observe an effect. Paugh et al. [22] also reported activation of PARP cleavage after treating Jurkat T-cells with 10 μM SKI-1. We observed this activity after 1a treatment, but only if the inhibitor was present for 16 h at a concentration (10 μM) far in excess of that required to inhibit SphK1 effectively (Figure 3b ). Since SKI-1 was not available to us for direct comparison, we tested the widely used inhibitor, SKI-II [32] , a low-affinity non-selective SphK inhibitor (K i 12-40 μM) [21] that we have found previously to lower S1P levels 4-fold in U937 cells when added at 10 μM for 2 h [28] . In the present study, SKI-II inhibited ERK phosphorylation but, like 1a, only when added for >2 h to U937 cells. Likewise, cleavage of PARP in response to SKI-II treatment required extended (16 h) treatment of Jurkat T-cells.
To ascertain whether inhibition of SphK correlated with cytotoxicity, we treated cultures of U937 (Figure 4a ) and Jurkat Tcells (Figure 4b ) with 0.3-10 μM 1a or 1b for 24 h and assessed cell viability with an MTT assay. As shown in Figure 4 , both 1a and 1b exhibit cytotoxic effects on the cells, but only at concentrations far greater than those required to inhibit S1P synthesis. The threshold for cytotoxicity was approximately 1 μM, which is a value 10-fold higher than is required to significantly reduce S1P levels in these cells. Finally, we observed no change in the growth of U937 cells cultured in the presence of 1a at concentrations of up to 1.0 μM (results not shown).
Our results indicate that inhibition of SphK1 in U937 cells does not correlate with inhibition of Akt or ERK phosphorylation.
Because U937 cells are unusual in their constitutively high levels of pAkt and pERK, we considered the possibility that SphK1 may play a role in growth factor-mediated phosphorylation of Akt and ERK, a hypothesis that has been supported in several experimental models [23] . To test this hypothesis we used cultured human ovarian cancer SKOV3 cells. Unlike U937 cells, SKOV3 cells have low basal levels of pAkt and pERK, and pAkt and pERK can be stimulated by EGF treatment. SKOV3 cells, similar to U937 and Jurkat T-cells, are sensitive to inhibitor 1a as revealed by the reduction of S1P levels observed after treatment with 0.3 μM 1a (Figure 5a ). We found that S1P levels in SKOV3 cells rose in response to EGF treatment and that this increase in S1P was antagonized by inhibitor 1a, but not 1b, treatment (Figure 5b) . We observed a similar pattern regarding EGF-evoked increases in pAkt and pERK levels (Figure 5c ).
In vivo evaluation of 1a
Lastly, we determined whether 1a blocked SphK1 in animals. Hla and co-workers reported that intravenously administered C17-S1P was cleared from mouse circulation with a 15 min t 1/2 [33] . Therefore we reasoned that an effective SphK1 blockade in mice would likewise result in a rapid diminution of endogenous circulating S1P. To this end we determined the levels of Sph and S1P in the blood of mice that were injected intravenously with 1a or 1b and the levels of these sphingolipids as well as 1a or 1b were measured in blood samples obtained at various times after injection. We found that whole blood S1P levels dropped rapidly to about one-half of control levels shortly after injection of 1a. In contrast, the administration of the same dose (10 mg/kg) of the less potent enantiomer, 1b, or vehicle, did not change blood S1P levels ( Figure 6a) . As an additional assessment of target specificity, we injected 1a or vehicle into Sphk1 − / − mice. In these mice, the same dose of compound 1a did not change blood S1P levels (Figure 6a ). There was no significant change in blood Sph levels in either type of mouse (Figure 6b) . Finally, Figure 6 (c) shows that both 1a and 1b are rapidly cleared from circulation, i.e. >90 % of the compound was cleared from the bloodstream by 60 min after injection. We performed a parallel study in rats and observed the same result: a rapid decrease in blood S1P levels and rapid clearance of the test compounds. In the rat study, where blood was drawn over a 4 h time course, we found that blood S1P level returned to pre-dose levels at 2 h post-injection (results not shown).
DISCUSSION
The pro-survival, pro-migratory and mitogenic effects of S1P coupled with the inducibility of SphK1 by a wide variety of stimuli have generated repeated suggestions that SphK1 could be a viable therapeutic target for small molecule inhibition in diseases characterized by hyperproliferation, particularly cancer [34, 35] . Numerous studies deploying interfering RNA strategies implicate SphK1 in a variety of signalling cascades that lends credence to SphK1 as a drug target. However, the SphK1 inhibitors necessary to learn whether rapidly inhibiting enzyme activity recapitulates the effects observed after slowly decreasing protein levels are largely lacking. With few exceptions [36] , the inhibitors described heretofore are low potency (K i values are of the order of 10 μM), non-isotype selective [21] and have not been documented as inhibiting SphK1 enzymatic activity in cells or animals. Furthermore, most of these inhibitors are long chain bases that tend to be cytotoxic to cells, making their use at micromolar concentrations problematic. (a) Cultured U937 cells were treated with the indicated concentrations of compounds 1a and 1b (or 10 μM SKI-II) for the indicated times. Cells were then lysed and samples containing the same amount of protein (40 μg) were analysed by SDS/PAGE and Western blotting using primary antibodies against the phosphorylated (pERK and pAkt) and dephosphorylated forms of ERK and Akt. PD098059 (10 μM) was used as a positive control for inhibition of ERK phosphorylation. (b) Cultured Jurkat T-cells were treated with the indicated concentrations of compounds 1a and 1b, or 10 μM SKI-II, for 16 h. Cells were then lysed and analysed as described for (a) using primary antibodies against the phosphorylated (pAkt/pERK) and dephosphorylated forms of Akt/ERK, and the cleaved and uncleaved forms of Caspase 3 and PARP. Etoposide (5 μM) was used as a positive control for caspase activation. In both panels β-actin was used as a loading control.
In the present paper, we describe an inhibitor that selectively blocks SphK1. Our claim for selectivity is based on a rank order of IC 50 values in cells that matches the K i values (1a more potent that its enantiomer 1b) and the lack of an effect of 1a on circulating S1P levels in Sphk1 − / − mice. Although these results build confidence, we cannot rule out off-target effects on, for example, other proteins that bind Sph, by these long-chain bases particularly at micromolar concentrations. Concern about the nonspecific cytotoxicity of long-chain bases is addressed to some extent by the use of 1b. Ultimately, the specificity of SphK1 inhibition by small molecules is best established by comparison of multiple inhibitors with a variety of structures.
Compound 1a decreased S1P in cultured U937, Jurkat T-cells and SKOV3 cells and prevents the conversion of Sph to S1P in these cells. Furthermore, we observed no evidence of cell toxicity at concentrations (0.3 μM) of 1a that effectively inhibit SphK1 for treatment periods up to 24 h. The cellular toxicity that we did observe occurred at concentrations that far exceeded those required to block S1P production. Moreover, equivalent cytotoxicity was observed at equal concentrations of 1a and 1b despite their >100-fold difference in K I values at SphK1.
Our results do not support the contention of Paugh et al. [22] that a SphK1 blockade affects growth, viability or signalling in U937 cells within a 24-h time window. Indeed, we were unable to detect any effect on U937 cells despite a nearly complete blockade of the conversion of Sph into S1P by SphK1. Only when inhibitor was present at high concentrations (10 μM) could we evoke a response from these cells, and at these concentrations the enantiomers were equipotent, which suggests to us an off-target mechanism. However, we found that SphK1 blockade with 1a did inhibit EGF stimulated accumulation of pAkt and pERK in SKOV3 cells. At this juncture, we do not know whether the S1P produced in response to EGF is acting through cell surface S1P receptors in an autocrine fashion or through some other intracellular mechanism that is independent of canonical S1P receptors [37] .
The concept of sphingolipid homoeostasis, i.e. cells balancing the relative levels of Sph/ceramide and S1P, is intriguing. An implication of this idea is that blockade of the conversion of Sph into S1P will both lower S1P and raise Sph and ceramide levels. Reportedly, Sph levels are approximately 10-fold higher than S1P in cells and ceramide levels are another log order higher [38] . Given this 100-fold difference between cellular levels of ceramide and S1P, we thought it unlikely that SphK inhibition would increase ceramide substantially. Indeed, when SphK1 is inhibited by 1a, S1P levels decrease more than 10-fold, whereas Sph levels rise barely 2-fold in U937 cells and changes in ceramide levels are undetectable (Figure 1) .
The rapid decrease in circulating S1P in response to SphK1 inhibition by 1a observed in vivo is intriguing. In addition to providing compelling evidence of the selectivity of 1a for the SphK1 isotype, this result indicates that blood S1P levels can serve as a biomarker of SphK1 inhibition. We do not know the mechanism(s) whereby S1P is cleared from blood, but an obvious potential route is dephosphorylation catalysed by the ubiquitous lipid phosphate phosphohydrolases; another is by S1P lyase. We found that the S1P concentration in whole mouse blood is approximately 3 μM (Figure 6a ), whereas that in mouse plasma is approximately 10-fold lower (results not shown). Such a difference is expected in view of the observation that erythrocytes have high S1P levels [39, 40] . It will be interesting to learn whether, following SphK1 inhibition, plasma S1P levels remain constant whereas whole blood S1P stores are depleted. Regardless of the mechanism(s), our results suggest that the S1P Figure 5 Effect of SphK1 inhibition on S1P levels and Akt/ERK phosphorylation by SKOV3 cells (a) Cultured SKOV3 cells were treated with 0.3 μM 1a or 1b for 1 h. Cells were then harvested and the amount of cell-associated S1P was measured by LC-MS. (b) SKOV3 cells were treated for 1 h with 0.3 μM 1a or 1b and then stimulated with EGF (10 ng/ml) for 10 min. Cells were then harvested, lysed and the amount S1P was measured by LC-MS. (c) Cultured SKOV3 cells treated as described in (b) were analysed by Western blotting using primary antibodies against pAkt/pERK, total Akt/ERK and β-actin (loading control). The MAPK (mitogen-activated protein kinase) inhibitor PD098059 was used as a positive control. **P < 0.01, ***P < 0.001 (one-way ANOVA, and Dunnett's multiple comparison post test, compared with control).
pool in blood is in a state of rapid flux. Interestingly, a structurally similar bioactive lysophospholipid, lysophosphatidic acid, also turns over rapidly in circulation [41, 42] .
The existence of S1P in the bloodstream at low micromolar levels and in plasma at high nanomolar levels suggests a physiologic role for this molecule. Studies with the S1P receptor agonist pro-drug, FTY720 (fingolimod), led to the realization that S1P is involved in egress of lymphocytes from secondary lymphoid tissues and implicated S1P in controlling heart rate [43] . A third role for circulating S1P was suggested by the administration of S1P1/3 receptor antagonists that elicit vascular leakage acutely in mice [44, 45] . The decrease in blood S1P in response to SphK1 inhibition provides, in theory, a method to test whether acute changes in circulating S1P levels influence blood lymphocyte levels, heart rate and/or capillary integrity. 
Wild-type or Sphk1
− / − mice were dosed with 10 mg/kg of compounds 1a or 1b or vehicle via the tail vein. Blood samples were obtained after injection at the times indicated. Levels of S1P, Sph and compounds 1a or 1b in blood samples were measured by LC-MS. (a) S1P; (b) Sph, (c) compounds 1a and 1b. The lower blood levels of S1P observed in Sphk1 − / − mice are consistent with the previous studies [48, 49] . Results are means + − S.D. of three measurements in different animals. Sphk1 − / − mice are referred to as 'SK1 − / − '. **P < 0.01, ***P < 0.001 (repeated measures two-way ANOVA, and Bonferroni's multiple comparison post test).
Signalling at the S1P1 receptor is critical for proper lymphocyte egress from lymphoid tissues [46] . Therefore we considered using 1a to induce lymphopenia in animals. However, the short t 1/2 of 1a in vivo coupled with the observation that normal lymphocyte trafficking is maintained until plasma S1P becomes very low [46] makes detecting changes in circulating lymphocytes problematic with this particular compound. Injected S1P slows the heart rate in anaesthetized rats [47] , but we do not yet know whether the 50 % reduction in blood S1P achieved after 1a injection increases heart rate in rodents. We have measured pulmonary leakage of Evans Blue dye in mice injected with 1a to assess the effects of a decreased S1P circulatory tone on the endothelial barrier.
However, our results to date have been inconsistent. In future studies, we will attempt to magnify the effect of SphK1-selective inhibitors by using SphK2-null (Sphk2 − / − ) mice and analogues that persist longer in vivo.
In sum, the administration of compound 1a mounts a sustained, selective blockade of SphK1 in cultured cells and a transient, blockade in vivo. This inhibition neither induces a cell-stress response nor limits proliferation by U937 cells, but the inhibition does blunt an EGF response in SKOV3 cells. Although too short lived in vivo to be useful in animal models of disease, 1a is adequate in establishing persistent SphK1 inhibition in cultured cells. We will be particularly interested to learn how well the results obtained by the slow onset, partial reduction in SphK1 protein levels correlate with the rapid inhibition of SphK1 catalytic activity achieved by compounds such as 1a. 
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